Diffusion Pharmaceuticals Inc  

(Public, OTCMKTS:DFFN)   Watch this stock  
Find more results for DiFusion, Inc
+0.23 (18.40%)
Feb 5 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.26 - 1.48
52 week 0.40 - 3.10
Open 1.26
Vol / Avg. 3,913.00/9,706.00
Mkt cap 27.55M
P/E     -
Div/yield     -
EPS -1.36
Shares 18.61M
Beta -0.11
Inst. own 0%
Nov 12, 2015
Q3 2015 RestorGenex Corp Earnings Release

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -176.72% -46.96%
Return on average equity -208.50% -64.33%
Employees 8 -
CDP Score - -


2020 Avon Ct Ste 4
United States - Map
+1-434-2200718 (Phone)

Website links


Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on the results of cancer treatments, such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple Food and Drug Administration (FDA) Orphan-designated indications. Its product pipeline includes Trans Sodium Crocetinate (TSC), Glioblastoma Program, Pancreatic Cancer Program and Brain Metastases Program. It is developing TSC for the treatment of life-threatening cancers in which tumor hypoxia (oxygen deprivation) diminishes the effectiveness of radiation therapy and chemotherapy. The Company’s TSC has received Orphan Drug Designation from the FDA for use in various cancers. TSC focuses on the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells vulnerable to the therapeutic effects of conventional radiation and chemotherapy.